NCT06610760View on ClinicalTrials.gov

Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia

PHASE4RecruitingINTERVENTIONAL

Enrollment

196

Participants

Timeline

Start Date

November 12, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

Gastric Intestinal Metaplasia

Interventions

DRUG

Ursodeoxycholic Acid

Subjects will be instructed to take one capsule (250mg) of ursodeoxycholic acid three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.

DRUG

Placebo

Subjects will be instructed to take one capsule (250mg) of placebo three times daily, and visit the hospital every 4 weeks for evaluation of the subjective symptoms and to receive a new supply of medication.

Trial Locations (1)

710032

RECRUITING

Xijing hospital, Xi'an

All Listed Sponsors

lead

Yongquan Shi

OTHER

NCT06610760 - Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia | Biotech Hunter | Biotech Hunter